US Patent

US9180091 — Soluble estradiol capsule for vaginal insertion

Method of Use · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a soluble estradiol capsule for vaginal insertion to treat vulvovaginal atrophy.

USPTO Abstract

According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2317`	—	Estrace
`U-2317`	—	Estrace

Patent Metadata

Patent number: US9180091
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-21
Drug substance claim: No
Drug product claim: Yes
Assignee: TherapeuticsMD Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.